Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Bead-Based Assay Kits to Boost Metabolic and Hormone Research

By BiotechDaily International staff writers
Posted on 28 Jul 2014
Bio-Rad\'s Bio-Plex Pro RBM Magnetic Bead-Based Assay
The Bio-Plex Pro RBM Magnetic Bead-Based Assay (Photo courtesy of BIO-RAD LABORATORIES)
A new line of magnetic bead, microtiter plate-based metabolic assay kits is now available for use by biotech and other life science researchers.

The Bio-Rad Laboratories, Inc. (Hercules, CA, USA) Bio-Plex Pro RBM Human Metabolic and Hormone Assay line comprises kits for the analysis of seven panels of highly relevant biomarkers involved in diabetes, obesity, metabolic syndrome, cardiovascular disease (CVD), and hormonal control of metabolism and reproductive organs. The kits were developed in partnership with Myriad RBM, Inc., (Austin, TX, USA).

In the standard format, each kit contains one 96-well microtiter plate, magnetic capture beads, detection antibodies, standards, two-level controls, diluent, buffers, streptavidin-PE, and plate seals for the detection of up to eight human metabolic markers.

The assays are built on a magnetic bead platform, which allows data to be reported within three and a half hours. The kit format enables robust quantification of multiple proteins in human serum, plasma, and cell culture media samples. Kits are offered for research involving gut hormones and adipokines, pituitary hormones, diabetes (type I and type II), metabolic syndrome, obesity, CVD, and inflammation.

The Bio-Plex Pro RBM Human Metabolic and Hormone Assay line of kits is compatible with the Bio-Plex 100/200, Bio-Plex 3D, and Bio-Plex MAGPIX analytical platforms, as well as all other Luminex-based xMAP instruments and software.

Related Links:
Bio-Rad Laboratories, Inc.
Myriad RBM, Inc.




Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
Free digital version edition of Bio Research International sent by email on regular basis
Free print version of Bio Research International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of Bio Research International in digital format
Free Bio Research International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?


Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.